Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cardiac resynchronization--a heart failure perspective.

Dee Ann Rivera1, Michael R Bristow

  • 1Division of Cardiology, University of Colorado HSC, Denver, Colorado 80262, USA.

Annals of Noninvasive Electrocardiology : the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc
|November 9, 2005
PubMed
Summary

New heart failure treatments, including biventricular pacing and implantable cardioverter-defibrillators (ICDs), significantly improve outcomes and reduce mortality in advanced heart failure patients. Device and drug therapies offer additive benefits.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Subgroups and Special Populations in Heart Failure Clinical Trials: Insights From the HFC-ARC Expert Consensus Panel.

JACC. Heart failure·2026
Same author

Myocardial Recovery With Mechanical Circulatory Support Is Linked to Alternative Splicing and Subcellular Localization of CAMK2D.

Circulation·2026
Same author

JACC: Basic to Translational Science: Honoring the Top Reviewers of 2024.

JACC. Basic to translational science·2025
Same author

Backbone of Trials in a Challenging Environment: Recognizing Site-Based Research Teams.

Circulation. Heart failure·2025
Same author

β<sub>1</sub>- and β<sub>2</sub>-adrenergic Receptor Haplotypes Regulate Therapeutic Responses to Placebo and the Biased Ligand β-blocker Bucindolol.

medRxiv : the preprint server for health sciences·2025
Same author

Exercise Mitigates Diabetic Cardiomyopathy by Suppressing Ferroptosis via <i>N</i>-Acetyltransferase 10.

Circulation research·2025

Area of Science:

  • Cardiology
  • Medical Devices
  • Pharmacology

Background:

  • Heart failure pharmacologic therapy has reduced mortality by 30-40% in dilated cardiomyopathy, but progress has slowed due to the success of neurohormonal inhibitors.
  • New therapies must be developed against the backdrop of maximal neurohormonal inhibition.
  • Electrophysiologic device trials demonstrate that new heart failure therapies can still be developed.

Purpose of the Study:

  • To evaluate the impact of cardiac resynchronization therapy (CRT) and implantable cardioverter-defibrillators (ICDs) on major clinical outcomes in advanced heart failure patients.
  • To assess the additive benefits of device/drug therapy in heart failure management.

Main Methods:

  • Analysis of data from electrophysiologic device trials, specifically COMPANION and CARE-HF.

Related Experiment Videos

  • Focus on advanced heart failure patients with mechanical intraventricular dyssynchrony indicated by increased QRS duration.
  • Evaluation of biventricular pacing (CRT) and ICD implantation.
  • Main Results:

    • Cardiac resynchronization therapy (CRT) demonstrated significant improvement in major clinical outcomes, including mortality, in advanced heart failure patients with intraventricular dyssynchrony.
    • The addition of an implantable cardioverter-defibrillator (ICD) further reduced mortality by decreasing sudden cardiac death.
    • Device/drug therapy proved to be additive in heart failure treatment.

    Conclusions:

    • Device/drug therapy represents a significant advancement in heart failure management.
    • These findings herald a new era of multi-modality therapeutic approaches for heart failure.
    • CRT and ICDs are crucial components in managing advanced heart failure, particularly in patients with QRS prolongation.